An Official Website of the United States Government
Non-Invasive Optical Determination of GFR
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 2
-
Fiscal Year: 2009Title: Non-Invasive Optical Determination of GFRAgency: HHSContract: 2R42DK079477-02Award Amount: $999,981.00
Abstract:
DESCRIPTION (provided by applicant): PharmacoPhotonics (FAST Diagnostics), LLC proposes research to extend the Phase I STTR leading to a novel 2-photon in vivo fluorescence method for monitoring glomerular filtration rate (GFR) in acute kidney injury (AKI) . AKI remains a vexing clinical problem resulting in unacceptably high patient mortality, development of chronic kidney disease and enhanced progression to end stage renal disease. Although clinical risks factors for developing AKI have been identified, th ere is no reasonable surveillance technique ( biomarker ) to definitively and rapidly diagnose or determine the extent of severity of AKI in any patient. Since patient outcomes correlate with the extent of injury, and effective therapy requires early inter vention, the ability to rapidly diagnose and stratify patients by their level of kidney injury is paramount for clinical progress in this field. Therefore, FAST is developing and characterizing an optical measurement technique utilizing a novel minimally i nvasive Ratiometric Fluorescence Device (RFD) that can rapidly, accurately, and repetitively quantify the GFR, independent of serum or urinary measurements. FAST intends to more thoroughly characterize this approach using multi-photon microscopy and their patented ratiometric technique utilizing two fluorescent reporter molecules. This quantitative ratiometric optical approach minimizes the inherent limitations of intensity fluorescence determinations and allows for rapid and accurate determination of GFR. FAST will also initiate the development of a noninvasive device and marker molecules. Therefore, the purpose of this Phase II STTR project is to characterize the RFD in rats and then dogs, both under physiologic and AKI conditions, utilizing data on molecu lar markers gained in the Phase I study. FAST will then extend these observations into animal models of AKI including ischemia, sepsis, and nephrotoxins, such as aminoglycosides and radiocontrast agents. These studies will set the foundation for use of the RFD in human studies and further development of an initial noninvasive optical detection apparatus. PUBLIC HEALTH RELEVANCE: Acute Kidney Injury (AKI) is a major and rapidly increasing cause of morbidity and mortality in hospitalized patients. Unfortunate ly, there is at present no diagnostic method to either rapidly diagnose and or quantify the extent of AKI, both of which are known to be important in the prognosis and treatment. FAST Diagnostics has developed a ratiometric fluorescent device and an associ ated technique allowing for rapid quantification of kidney function during AKI.Small Business Information at Submission:Research Institution Information:PHARMACOPHOTONICS, LLC
PHARMACOPHOTONICS, Inc 351 W. 10th St. INDIANAPOLIS, IN 46202EIN/Tax ID: 120582396DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: NoINDIANA UNIVERSITY
INDIANA UNIVERSITY
601 E KIRKWOOD AVE
BLOOMINGTON, IN 47405-1223RI Type: Nonprofit college or university
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 89513 |
Program Year/Program: 2009 / STTR |
|
Agency Tracking Number: DK079477 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |